MedImmune Provides Fellowship Grants To Six Pediatric Respiratory Researchers
07 Mai 2007 - 5:05PM
PR Newswire (US)
- Jayson Luma, M.D., The Women's and Children's Hospital of
Buffalo, Receives $35,000 Grant - TORONTO, May 7
/PRNewswire-FirstCall/ -- Underscoring its commitment to pediatric
medicine, MedImmune, Inc. (NASDAQ:MEDI) has divided a 2007 grant
for $210,000 for pediatric respiratory research among six pediatric
fellows; each recipient's institution will receive a $35,000 grant
to support the fellow's research. The Pediatric Fellowship Program,
sponsored by MedImmune, is designed to stimulate interest and
research in the area of viral respiratory pathogens among
infectious disease fellows in the United States. The six recipients
were acknowledged on Sunday, May 6, 2007 at a reception coinciding
with the annual meeting of the Pediatric Academic Societies (PAS)
in Toronto, Canada. "This fellowship program supports and
encourages research critical to the understanding of potentially
severe pediatric infectious diseases such as respiratory syncytial
virus (RSV) and influenza," said Frank J. Malinoski, M.D., Ph.D.,
senior vice president, medical and scientific affairs. An
independent advisory board consisting of 15 pediatric infectious
disease physicians from across the United States selected the six
fellowship recipients. All candidates were required to be full-time
fellows in an American Board of Pediatrics-accredited fellowship
program and conducting original research as their primary focus.
The 2007 Pediatric Fellowship Program grant recipients include: --
Steven Grube, M.D. University of Texas Southwestern Medical School
Project Title: The Role of Viral Persistence in Respiratory
Syncytial Virus (RSV) - Induced Long Term Lung Disease -- Laura
Hammitt, M.D. The Children's Hospital/University of Colorado Health
Sciences Center Project Title: Vaccine-induced Immunologic Defense
Against Influenza in the Respiratory Tree -- Michele Kong, M.D.
University of Alabama at Birmingham, AL Project Title: Matrix
Metalloproteinases and Respiratory Syncytial Virus Infection --
Jayson Luma, M.D. The Women and Children's Hospital of Buffalo
Project Title: Arachidonic Acid Metabolites in Human Infants and
Mouse Models of Respiratory Syncytial Virus Infection -- Victoria
McMeen, M.D. University of Virginia Project Title: Viral
Replication and Clearance in Asthmatic Versus Non-Asthmatic
Individuals During Experimental Infections with Rhinovirus --
Archana Singh, M.D. Winthrop University Hospital Project Title:
Examination of the Role of Respiratory Syncytial Virus Infection in
the Pathogenesis of Lung Disease in Cystic Fibrosis MedImmune's
Pediatric Fellowship Program is one example of the company's
broader, ongoing commitment to research and pediatric health. In
another example, the Pediatric Infectious Diseases Society (PIDS),
supported by grants from MedImmune, will present the third annual
MedImmune Career Development Award in Pediatric Infectious Disease
and the second annual Viral Respiratory Disease Fellowship tonight
at a PIDS Dinner and Awards Banquet also being held in conjunction
with the PAS annual meeting. To date, MedImmune has invested more
than $2 billion in research funds to develop new and
next-generation medicines against respiratory viruses such as RSV
and influenza. About MedImmune, Inc. MedImmune strives to provide
better medicines to patients, new medical options for physicians,
rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help
people live better lives, the company is focused on the areas of
pediatric infectious diseases, cancer and inflammatory diseases.
With more than 2,500 employees worldwide, MedImmune is
headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com/ . Notice to
Investors and Stockholders of MedImmune This release is neither an
offer to purchase nor a solicitation of an offer to sell shares of
MedImmune. MedImmune stockholders are urged to read the relevant
tender offer documents from AstraZeneca PLC which have been filed
on May 3, 2007 because they will contain important information that
stockholders should consider before making any decision regarding
tendering their shares. AstraZeneca has filed tender offer
materials with the U.S. Securities and Exchange Commission, and
MedImmune has also filed a Solicitation/Recommendation Statement on
Schedule 14D-9 with respect to the offer. The tender offer
materials (including an Offer to Purchase, a related Letter of
Transmittal and certain other offer documents) and the
Solicitation/Recommendation Statement contain important
information, which should be read carefully before any decision is
made with respect to the tender offer. The Offer to Purchase, the
related Letter of Transmittal and certain other offer documents, as
well as the Solicitation/Recommendation Statement, are available
for free at the U.S. Securities and Exchange Commission's web site
at http://www.sec.gov/, at AstraZeneca's website at
http://www.astrazeneca.com/ or at MedImmune's website at
http://www.medimmune.com/ . DATASOURCE: MedImmune, Inc. CONTACT:
Kate Barrett of MedImmune, Inc., +1-301-398-4320 Web site:
http://www.medimmune.com/
Copyright
Medimmune (NASDAQ:MEDI)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Medimmune (NASDAQ:MEDI)
Historical Stock Chart
Von Dez 2023 bis Dez 2024